Clinical Trials Browser

Phase 2 × tislelizumab × Dermatologic × Clear all

Uveal Melanoma

NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT04924413 2024-07-03

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Phase 2 Terminated

9 enrolled

Dermatologic

Melanoma

NCT05104801 2021-11-04

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Phase 2 Unknown

37 enrolled

Dermatologic

Melanoma

Clinical Trials

SITISVEAL

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma